PapersPMID:32958070
Effects of whey protein on glycemic control and serum lipoproteins in patients with metabolic syndrome and related conditions: a systematic review and meta-analysis of randomized controlled clinical trials.
No finding here moved its endpoint.
What did not
1 findingHow to read these marks →“Whey protein intake did not have any effect on FPG (17 studies with 20 effect sizes) (WMD: -0.61; 95% CI: − 2.83, 1.62) (Table 2 & Fig. 2a).”
- Study
- meta-analysis
- Effect
- −0.61 mean difference, 95% CI −2.83 to 1.62
- Dose studied
- daily doses from about 4 g to 90 g, or 0.4 to 0.5 g/kg; trials lasted 4 to 24 weeks
- Population
- People with metabolic syndrome or related conditions (overweight or obesity, type 2 diabetes, hypertension, dyslipidaemia, polycystic ovary syndrome); 17 trials with 20 effect sizes
Study record
- Design
- meta-analysis
- Species
- human
- Population
- Patients with metabolic syndrome and related conditions (obesity, diabetes, hypertension), 1103 subjects across 22 RCTs
- Participants
- 1,103
- Comparator
- an active treatment / placebo
- Duration
- not reported
- Endpoints measured
- 35
- Declined
- the paper never states the instrument the node requires